InvestorsHub Logo
Followers 58
Posts 5857
Boards Moderated 0
Alias Born 02/09/2005

Re: None

Wednesday, 01/11/2023 12:20:23 PM

Wednesday, January 11, 2023 12:20:23 PM

Post# of 1726
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.


The dumbest people I know are those who know it all.
Malcolm Forbes

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DARE News